Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry <\/p>\n
of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the <\/p>\n
first time, a new policy to expedite the review of generic drug applications where competition is limited.<\/p>\n","protected":false},"excerpt":{"rendered":"
Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review … Continue reading FDA Tackles Drug Competition to Improve Patient Access<\/span>